Active surveillance for favorable-risk prostate cancer: Is there a greater psychological impact than previously thought? A systematic, mixed studies literature review. by Ruane-McAteer, E. et al.
 This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process which may 
lead to differences between this version and the Version of Record. Please cite this article as 
doi: 10.1002/pon.4311 
 
This article is protected by copyright. All rights reserved. 
Manuscript title: Active Surveillance for Favourable-Risk Prostate Cancer: Is there a 
Greater Psychological Impact than Previously Thought? A Systematic, Mixed Studies 
Literature Review. 
Running Head: The Psychological Impact of Active Surveillance for Prostate Cancer  
1. *Eimear Ruane-McAteera  
eruanemcateer01@qub.ac.uk +44(0)2890972684  
*Corresponding author 
2. Prof Sam Porter, PhDa  
3. Prof Joe M. O’Sullivan, MDb,c  
4. Dr Olinda Santin, PhDa   
5. Dr Gillian Prue, PhDa  
aSchool of Nursing and Midwifery, Medical Biology Centre, Queen’s University, 97 Lisburn 
Road, Belfast BT9 7BL 
b
The Northern Ireland Cancer Centre (NICC), Belfast City Hospital, 51 Lisburn Road, 
Belfast BT9 7AB 
c
Centre for Cancer Research and Cell Biology (CCRCB), Queen's University Belfast, 97 
Lisburn Road, Belfast BT9 7AE 
Funding: This review was completed for part-fulfilment of ER’s PhD. No outside funding 
was used.  
Conflict of interest: The authors declare no conflicts of interest.  
Author contribution 
ER and GP were responsible for the design of this systematic review, data acquisition, 
analysis and interpretation. OS aided in this process, arbitrating any disagreement. SP and 
JO’S advised on design and evidence acquisition. ER drafted the article. GP, OS, SP and 
JO’S critically revised the manuscript. All authors approved the final submission.  
  
 This article is protected by copyright. All rights reserved. 
Abstract  
Objective 
Active Surveillance (AS) allows men with favourable-risk prostate cancer (PCa) to avoid or 
postpone active treatment and hence spares potential adverse side effects for a significant 
proportion of these patients. Active surveillance may create an additional emotional burden 
for these patients.  
The aim of the review was to determine the psychological impact of AS to inform future 
study in this area and to provide recommendations for clinical practice.  
Methods 
Studies were identified through database searching from inception to September 2015. 
Quantitative or qualitative non-interventional studies published in English that assessed the 
psychological impact of AS were included. The Mixed Methods Appraisal Tool was used to 
assess methodological quality.  
Results 
Twenty-three papers were included (20 quantitative, 3 qualitative). Quantitatively, the 
majority of patients do not report psychological difficulties, however when appropriateness of 
study design is considered, the conclusion that AS has minimal impact on wellbeing, may not 
be accurate. This is due to small sample sizes, inappropriately timed baseline, and 
inappropriate/lack of comparison groups.  In addition, a mismatch in outcome was noted 
between the outcome of quantitative and qualitative studies in uncertainty, with qualitative 
studies indicating a greater psychological impact.   
Conclusions  
Due to methodological concerns, many quantitative studies may not provide a true account of 
the burden of AS. Further mixed-methods studies are necessary to address the limitations 
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highlighted and to provide clarity on the impact of AS. Practitioners should be aware that 
despite findings of previous reviews, patients may require additional emotional support. 
Keywords 
Prostatic Neoplasms. Cancer. Oncology. Active Surveillance. Anxiety. Depression. 
Uncertainty.  
 
Background 
Active surveillance (AS) was developed in response to the increasing prevalence of lower 
risk prostate cancer (PCa) in older men [1]. AS allows the majority of patients with lower risk 
PCa to avoid active treatment and hence the side-effects associated with such therapy [2]. 
Although AS protocols may vary, they usually involve Prostate-Specific Antigen (PSA) tests 
and Digital Rectal Examinations (DRE) at regular intervals, and annual/biannual biopsies. In 
recent years, regular multi-parametric MRI scans of the prostate have become part of AS 
protocols [3]. Numerous studies have documented the appropriateness of AS from a medical 
perspective, however the psychological impact of AS remains understudied [4]. In spite of 
this, the assumption is that men undergoing AS do not require additional support, 
psychological or otherwise, throughout this monitoring period. This assumption can partly be 
attributed to results of systematic reviews in this area, for example: a recent exclusively 
quantitative systematic review [5] concluded that men on AS reported no major difficulties in 
quality of life (QoL) or psychological wellbeing. However, this review utilised narrow 
inclusion and exclusion criteria and excluded studies referring to Watchful Waiting (WW), a 
management approach that is palliative in nature but often incorrectly used interchangeably 
with AS. This omission may have led to the exclusion of some relevant papers. The lack of 
critical appraisal meant study quality was not taken into consideration in the interpretation of 
the results.  
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In a similar quantitative review [6], it was concluded that AS was unlikely to be associated 
with an adverse effect on general psychological wellbeing. In this instance, studies describing 
WW or ‘no treatment’ were included. However, no distinction was made between those 
studies describing AS versus true WW. Although the methodological quality of studies was 
assessed, this was not considered when interpreting the results of the review. In addition, 
neither of these reviews included qualitative studies, which meant that an important 
opportunity to better understand the experiences of patients was missed. It is our contention 
that a mixed methods review that includes both qualitative and quantitative studies would 
allow for richer experiential data to be included without compromising generalisability 
achieved using quantitative methods [7]. 
Aims 
The aim of this systematic mixed studies review was to synthesise and appraise the 
quantitative and qualitative knowledge to develop a more comprehensive picture of published 
studies reporting the psychological impact of undergoing AS.  
Evidence acquisition  
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines were used for the conduct and reporting of this systematic review [8].  
Eligibility criteria 
Inclusion criteria: non-interventional studies published in English assessing the psychological 
impact of AS in lower-risk PCa, including studies comparing AS with AT. Studies referring 
to WW were included when the definition was that of AS.  
Exclusion criteria: review articles, editorials, comments, intervention studies (e.g. studies that 
included a psychosocial intervention), needs assessments and studies assessing quality of life 
(QoL). While QoL is an important factor, it was deemed inappropriate for the present review 
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due to the insensitivity of general QoL measures in assessing clinical change in psychological 
functioning [9].  
Information sources 
Medical and nursing databases were searched from inception between August and September 
2015 with no limitations on time, using a predetermined search strategy (Fig.1.). Titles and 
abstracts were screened by ER and GP based on the inclusion/exclusion criteria, where there 
was doubt regarding the eligibility of a particular title or abstract the record was retained for 
full-text screening. OS arbitrated any disagreement at the full-text screening stage.  
Search 
Figure 1. PRISMA Flow Diagram  
Study selection 
Qualitative and quantitative findings related to the prevalence and predictive/protective 
factors of psychological variables were reported, namely depression, anxiety, and uncertainty. 
ER and GP extracted data from each article and applied the quality appraisal tool, OS 
arbitrated any disagreement.  
Data collection process 
The Mixed Methods Appraisal Tool (MMAT) [10], an appropriate, reliable and efficient tool 
for mixed studies reviews was used to assess study quality [11]. ER and GP completed the 
MMAT for each study, with OS arbitrating. This appraisal directly informed the 
interpretation of study findings.  
Results 
Synthesis of results 
Twenty-three papers were included, 20 quantitative [12-31], and 3 qualitative [32-33]. Nine 
were longitudinal [15, 18-21, 23, 25-27] with a follow-up period ranging from 9 months [25] 
to 3 years [18]. Attrition in these studies varied, with response rates at follow-up time-points 
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ranging from 13% [21] to 89% [15]. Three studies did not report attrition [18, 20, 23]. Four 
of the 9 longitudinal studies had follow-up response rates of >70% [15, 19, 25, 27], whereas 
others reported more conservative follow-up response rates of <60% [21, 26]. Fourteen were 
cross-sectional [12-14, 16-17, 22, 24, 28-34], with time since diagnosis ranging from 2 
months [23-24, 29] to 136 months [22]. Six papers referring to WW, yet providing definitions 
for AS, i.e. not palliative care, were included [17-18, 23, 32]. Seven papers included 
comparison groups; the majority compared AS patients with patients opting for AT [14, 15, 
18, 21, 23, 26], one was a comparison of North American and Irish AS patients [17]. 
Breakdown of individual sample sizes and countries of origin are detailed in Table 1. The 
pooled number of AS patients across the twenty-three papers amounted to 1777 men.  
Quality appraisal 
Using the MMAT [11], papers were scored against four main criteria associated with the 
specific research design; four papers met 100% of criteria; 15 met 50-75%; and four met only 
25% of the methodological quality criteria (Table 1). Failure to justify sample size, 
inappropriate/no comparison group, and lack of baseline measures were the most frequently 
observed methodological issues.  
Depression 
Twelve quantitative studies investigated depression in this population, reporting data for 1007 
AS patients in total. Five studies included AT men as a comparison group [14, 15, 18, 23, 
26]. Six different scales were used to assess depression (Table 2).  
Quality appraisal 
Eight of the 12 studies were considered high quality studies (75%-100% of methodological 
criteria was met). Two of the studies fulfilled 50% of the methodological criteria [15, 22]; 
with an insufficient response rate, failure to provide reasons for non-participation and an 
inability to determine if the sample was representative due to the authors failing to report 
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demographic information per treatment group included were limitations of these studies. Two 
studies met only 25% of the methodological quality criteria [16, 29]. The first [16] failed to 
justify sample size, provide reasons for non-participation and recruited from support groups, 
leading to a potential selection bias. Response rate was also not reported [16]. In the second 
[29], the HADS was used inappropriately to diagnose clinical depression. HADS does not 
include somatic symptoms that makes up the diagnostic criteria of clinical depression 
therefore the measure used does not address the aims of their study. Other methodological 
issues included lack of a representative sample, as despite the use of multiple sites 95% of the 
sample identified as white British. The authors’ failure to include a control group also 
reduced the MMAT score attributed to the study. The study did however include a large 
number of participants (n=313) and their response rate was high (73.47%).  
Prevalence   
Four studies reported prevalence data for depression [14, 21, 25, 29]. Generally, the 
prevalence of depression was low; two studies reported mild depression ranging from 4-11% 
[14, 21], with moderate-severe depression reported in less than 5% of both AS and RP 
patients [21]. One study reported clinically significant depression in 12.5% of their sample 
[29]. There was disagreement regarding the severity of depression in comparison to non-
cancer men. One study reported that although mild, depression was higher than literature 
reporting depression scores for men without a PCa diagnosis [14]. Conversely, depression 
levels were reportedly similar to normative data of clinical populations [25]. However, the 
latter study utilised a prospective, longitudinal design, with low attrition rates therefore 
reducing the impact of individual differences and increasing credibility of the findings.  
When compared to curative treatment, AS patients had the most favourable depression score 
[15, 26]. Although the difference between AS and RP patients immediately post-
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diagnosis/early treatment was statistically significant, clinical significance was not reported 
[15].    
One low quality study [29] reported a higher number of participants scoring within clinical 
levels; although the mean score of depression was low, 12.5% of patients’ scores suggested 
presence of clinical depression.  
Factors associated with depression  
Five studies attempted to identify factors predicting depression (Table 3). Neurotic patients 
who experienced a major life event additional to their diagnosis demonstrated increased 
depression [24]. Extraversion, continued sexual activity, and higher QoL were associated 
with decreased depression [24]. Similarly, patients with higher QoL and low neuroticism 
reported lower depression at diagnosis [25]. It was concluded that patient-bound factors, e.g. 
personality, were the most important determinants of depressive symptoms [13, 15, 24]. Lack 
of a partner and impaired mental health (MH) were both predictive of poorer wellbeing [13]. 
Patients enrolled in AS protocols soon after diagnosis were more likely to adopt poor coping 
strategies and demonstrate maladaptive adjustment to cancer; these patients had less time to 
seek information to support their choice of AS and therefore understand that their PCa was 
manageable [13]. 
Change in depression over time  
Six studies assessed depression longitudinally [15, 21, 23, 25-27]. Depression was reported to 
decrease with time in five studies [15, 21, 23, 26-27] for both mild [15, 21] and clinically 
significant depression [15, 29]. Conversely, in another high quality study with one of the 
lowest attrition of all included studies, depression remained stable up to 18-months post-
diagnosis [25]. A high quality cross-sectional study [14] reported a correlation between 
increased time since diagnosis and increased depression; a finding that must be treated with 
caution given the limitations of cross-sectional designs.  
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Anxiety  
Eighteen quantitative studies measured anxiety in 1639 AS patients [12-15, 18-30], using 
eight different scales (Table 2). Six studies included comparison groups of AT men [14, 15, 
18, 21, 23, 26]. 
Quality appraisal 
Eleven of the 18 studies assessing anxiety met 75% or 100% of the methodological quality 
criteria set out in the MMAT. Four met 50% of the criteria [12, 15, 18, 22], issues included a 
failure to report reasons for the low response rate [12, 18, 22], potential selection bias and 
failure to report the demographic information divided by treatment group [15], and no 
standardised tool for assessment of anxiety [18]. Three studies met 25% of the 
methodological quality criteria [16, 28, 29], issues with these studies included low sample 
size, potential selection bias, insufficient response rate or failure to report the response rate, 
reasons for non-participation not explained, failure to include a control group, and 
inappropriately timed baseline measurements. 
Prevalence  
The prevalence of anxiety ranged from 13-45% [12, 14, 21-22, 24-25, 27, 29-30]. One study 
reported up to 5% of patients with moderate-severe anxiety levels [21], and one with almost 
25% of participants with clinical levels of anxiety [29]. The majority of studies reported 
anxiety comparable or lower than data from non-clinical populations [12, 14, 22, 24]. One 
study [21] reported that the majority of participants had anxiety higher than that of non-
cancer men; however, the study cited to support these claims included no non-cancer data 
[35].  
AS men appeared to have low anxiety when compared to patients opting for AT [15]. Only 
one study directly contradicted these findings [26]; however this can be attributed to potential 
 This article is protected by copyright. All rights reserved. 
selection bias in the increased psychological dysfunction reported by those completing 
follow-up. 
Change in anxiety over time 
Six studies examined the temporal variability in anxiety [19-20, 21, 25-27]. With the 
exception of one study [25], statistically significant declines were observed over time.  
However, the one contradictory study [25] was of high methodological quality and 
maintained a high response rate during study follow-up. One study reported that although 
20% of patients suffered from clinically significant anxiety levels at baseline (within 6 
months of diagnosis), only 5% of the total sample chose to leave the AS protocol due to the 
psychological burden [27]. A significant decrease was observed in general anxiety and fear of 
disease progression over the course of the 18 month follow-up [27]. A number of other 
studies support these findings, also concluding that anxiety remained either stable or reduced 
over time [15, 20, 23-24, 26].  
In a 30-month follow-up study [19], anxiety reduced significantly at 18- and 30-months post-
diagnosis. Interestingly, 12- and 24-month follow-up data were not significant; typically this 
is when patients receive a biopsy to reassess their cancer and resulting course of treatment. 
Although, it must be noted that the trend of declining anxiety remained consistent across 
these time points.  
Longitudinal studies documenting a general decline in anxiety during AS are supported by 
two of the three cross-sectional studies that asked men to report number of months spent on 
AS [14, 21, 24]. Although not significant, increased time undergoing AS was associated with 
stable or decreased anxiety [22, 24]. One cross-sectional study however found a significant 
increase in anxiety with reported increased time since diagnosis [14]. 
Individual differences are an important factor and cross-sectional studies must be interpreted 
with caution despite apparent high methodological quality, this study design may simply not 
 This article is protected by copyright. All rights reserved. 
be appropriate to capture these men’s experiences. Based on the results of the previously 
reported, high quality study [19](Table 1), anxiety appeared to fluctuate, therefore, the time 
point at which the cross-sectional studies assess men would be a crucial in terms of the 
anxiety reported, and may explain some of the conflicting results discussed.  
Factors associated with anxiety 
The factors that appeared to be predictive of anxiety were: high neuroticism [24], younger 
age at diagnosis [14], low QoL and fear of cancer recurrence [12], impaired MH, lack of a 
partner and decreased number of cores taken at diagnostic biopsy [13], patients’ relationship 
status i.e. single/divorced [13, 29], misunderstanding of AS and resulting deferral of decision 
making to physician [13, 25, 30] (Table 3). The finding in relation to decreased number of 
cores taken at diagnostic biopsy, the authors suggested that this may a result of the patients’ 
perception, however inaccurate, that more of their cancer had been removed [13]. High 
neuroticism and high PSA were associated with increased PCa-specific anxiety [24]. Fear of 
disease progression, a component of PCa-specific anxiety, was identified as a trigger for 
discontinuation of AS in favour of AT [19]. The combination of high QoL and low 
neuroticism, was reported to be significant in minimising anxiety [25]. 
Uncertainty  
Six studies assessed uncertainty in 266 AS men. Three studies were qualitative [32-34], and 
three quantitative [17, 19, 28]. The quantitative studies used MUIS (Table 2) to measure 
uncertainty. Four additional papers were included in the uncertainty theme due to their 
assessment of decisional conflict [16, 24, 25, 27], a state of uncertainty, using the DCS (Table 
2). One study included a comparison group of Irish and North American AS patients [17]. 
Quality Appraisal  
Of the ten studies assessing uncertainty in the AS population, only one met 100% of the 
methodological quality criteria in the MMAT [24]. Three studies met 75% of the criteria [19, 
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25, 27], the absence of a comparison group in two of these studies prevented them from 
meeting all the methodological quality criteria [25, 27]; whereas potential selection bias in 
the recruitment of participants was an issue in the third study [19]. One qualitative study [32] 
also met 75% of the methodological criteria, as a result of failing to acknowledge their 
influence on their data. The two remaining qualitative studies [33, 34] met 50% of the 
methodological quality criteria due to the lack of acknowledgement of the researchers 
influence and the impact the context within which the research took place had upon the 
participants and resulting data. Two quantitative studies also met just 25% of the 
methodological criteria [16, 28]; failure to discuss the justification for their specific sample 
size, reasons for potential participants’ non-participation, response rate and issues with 
sampling were the reasons for this.  Finally, one additional paper met only 25% of the 
methodological criteria [17], this was due to the small sample (n = 29 participants), failure to 
apply appropriate inferential statistics as a result, as well as a failure to report the response 
rate.  
Prevalence 
None of the included studies reported the prevalence of clinically significant uncertainty 
using the MUIS. However, approximately 25% of patients scored clinical levels in DCS [24-
25, 27]. 
The perception of uncertainty 
The three qualitative studies included in this review identified similar themes regarding the 
nature of uncertainty experienced during AS, which contrasted with the quantitative findings. 
Men described ‘intolerable uncertainty’, a ‘Dangerous Wait’, characterised by uncertainty 
and a perception of ‘risking one’s life’ [33]. Although this study included only those who had 
converted to AT which may overstate the impact of uncertainty in AS. The other qualitative 
studies interviewed men who remained on AS [32, 34]. The theme ‘To be Uncertain, Afraid, 
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Worried’ emerged in one of these qualitative studies [32] in participants still undergoing AS 
with respondents describing constant threat, fear and worry. 
While patients understood the information about their diagnosis and prognosis intellectually, 
they had not integrated the message emotionally [32]. An overarching theme of uncertainty 
prevailed in each participant’s account, either implicitly or explicitly [32]. This theme was 
characterised similarly to those previously reported: persistent uncertainty surrounding 
mortality and potential spreading, potential need for AT, and patients’ ability to cope with 
treatment-induced morbidities. Participants described living in ‘shadowland’ while they 
‘waited for a disaster’ [232]. These subthemes were related back to patients’ masculine 
identities: pressure to maintain sexual function, and to continue to provide financial stability 
for their families [34]. Qualitatively, participants described uncertainty as featuring more 
significantly throughout the AS experience than the quantitative data suggested, a finding 
warranting further study.  
Change in uncertainty over time  
Three of the included uncertainty studies assessed uncertainty longitudinally [19, 25, 27]. 
Attrition was generally low at initial follow-up points, with response rates >70% [19, 25, 27], 
however after 18 month follow-up response rate dropped to 67% [27] and 44% after 2 year 
follow-up [19]. Uncertainty decreased from baseline to 18-months, however this decrease 
was neither statistically nor clinically significant [27]. Uncertainty at 6-months post-diagnosis 
predicted scores after 9-months of AS, suggesting uncertainty remains stable within the first 
year. A significant decrease was found from baseline up to 30-months post-diagnosis [19] 
however attrition may have been an issue. Conversely, qualitatively patients reported that 
uncertainty was time sensitive and peaked leading up to monitoring appointments, PSA and 
biopsy results [34].   
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Factors associated with uncertainty 
A number of factors were reported to increase uncertainty, including high neuroticism and 
increased role of clinician in decision-making [24, 25]. Patients who experienced depression, 
and had a more negative outlook were less satisfied with their treatment decision [16] (Table 
3). Uncertainty was reported to be a significant factor, and had a resulting impact on QoL and 
fear of disease progression [19, 28]. It was reported that it was the perception of danger 
associated with AS that increased uncertainty and had the resultant impact on QoL [28]. 
Anxiety was also associated with uncertainty [28].  
Factors reported to decrease uncertainty and decisional conflict were also discussed in the 
literature: high extraversion and the management of PCa in a university/specialist hospital 
appeared to be associated with lower decisional conflict [24, 25]. Palpable disease and older 
age at diagnosis reportedly had an additional favourable effect on the perceived risk of 
progression, a form of uncertainty, at follow up [25]. The finding in relation to palpable 
disease appears to be counter-intuitive, the authors posited that older patients with palpable 
disease at diagnosis may experience higher uncertainty initially, yet following a period of 
time on surveillance show greater improvement upon realising the feasibility of surveillance 
[25]. Favourable MH, optimism and higher self-efficacy (SE) as well as perceived 
consistency in medical information was associated with reduced uncertainty [16]. Qualitative 
data suggested stable or decreased disease characteristics at follow-up reduced uncertainty 
surrounding impending follow-up appointments and delays between monitoring appointments 
and receipt of results [34]. Patients also discussed feeling more secure when they saw the 
same clinician at follow-up appointments [34].  
The role of clinicians was ambiguous. They were both sources of uncertainty in that they 
were potentially bearers of bad news that the cancer had progressed further, and of security in 
that they provided patients with the reassurance of regular check-ups [32]. 
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Patients appeared to cope with uncertainty and decisional conflict in various ways, as was 
described in two qualitative studies [32, 34]. With regard to decision making, patients 
appeared to assume either a passive or active role in the process; while some patients opted to 
defer decision-making power entirely to their clinician, others chose to actively seek out 
further information or request a second opinion to engage more with the decision-making 
process [32]. Similarly, in response to diagnosis, some patients reported they decided to 
‘screen off’ their cancer by setting aside feelings of threat or completely denying the 
existence of their cancer, while others compensated for the perceived threat of their cancer 
via lifestyle change [32]. Patients also described control as central to their coping, this control 
was asserted by ‘living a normal life’ [34], similar to ‘screening off’ [32], or by ‘doing 
something extra’, a theme that also converges with lifestyle change discussed previously [32]. 
Discussion 
Main Findings 
From a quantitative perspective it would appear that men undergoing AS show favourable 
psychological wellbeing, with only a small number reporting maladjustment. These findings 
are consistent with those of previous systematic reviews [5, 6] in spite of differing inclusion 
criteria particularly in relation to inclusion of papers referring to AS as WW in the present 
review. While this convergence strengthens confidence in the results, a number of 
methodological issues remain outstanding. Specifically, a lack of appropriate 
comparison/control groups, and unavailability of baseline data leads to an inability to 
determine if men who choose AS are fundamentally less anxious than those who opt for 
immediate AT. Although potential predictors of adverse psychological adjustment were 
identified, these methodological limitations reduce confidence that they fully captured the 
experience of these men; therefore resulting implications for practice must also be treated 
cautiously. This lack of confidence is reinforced by conflicting results emanating from 
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different research designs. Particularly pertinent were differences in results relating to anxiety 
and depression between cross-sectional and longitudinal studies. It must be noted that 
although levels of anxiety and depression appeared to resolve over time when they were 
followed up longitudinally, attrition and response rate must be considered when evaluating 
the strength of the evidence. This is reflected in one study [25] that contradicted other 
longitudinal studies that reported decreasing anxiety and depression at later follow-up points, 
the same study had one of the lowest rates of attrition with an 84% response rate. This 
highlights the importance of reporting reasons for non-response and analysis of potential 
socio-demographic differences between complete and incomplete responders.  
As well as different findings resulting from longitudinal and cross-sectional evidence, further 
differences were observed in relation to qualitative and quantitative uncertainty data. In terms 
of prevalence, quantitative studies indicated that uncertainty appears to be low in this 
population. However when the nature of uncertainty was explored in qualitative studies, it 
appears to have a more significant impact on men than is reflected in the quantitative data. 
This idea is comparable to how quality of life is conceptualised in the severity of symptoms 
versus the ‘bother’/impact that is experienced by the patient as a result i.e. the impact of 
uncertainty on the individual cannot be ignored. Because no qualitative studies reported on 
anxiety or depression, potential differences in these areas remain moot, requiring further 
investigation.  
Limitations of the included studies  
Some questions need to be raised in relation to the comparators chosen in the reviewed 
studies. This is a significant issue because it is only through comparison that the extent of 
difficulties, or perhaps lack thereof, can be fully understood. Several studies included patients 
opting for AT as comparators, while others compared their results to reference values. 
Arguably, a more appropriate comparison is age-matched men with no PCa diagnosis in 
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addition to patients opting for AT. Due to the high incidence of undiagnosed lower-risk PCa 
in men over 60 years [36], it can be extrapolated that the psychological differences between 
patients and age-matched volunteers would be attributable to PCa, and the AS experience.   
A further criticism of the studies was that, because the patients sampled had already selected 
AS as a treatment course, it is possible that patients who were naturally less anxious, 
depressed, or uncertain, chose AS due to increased ability to cope. One study attempted to 
assess selection bias [21], observed that participants who completed follow-up reported 
greater psychological dysfunction than those lost to follow-up, illustrating an additional 
potential bias in terms of the type of patient that remains involved in psychological studies.    
None of the studies utilised a mixed-methods (MM) design and only a limited number were 
qualitative, and these only reported results for uncertainty. This is limiting in that men on AS 
are not being afforded the opportunity to express their interpretation of their experiences. 
MM research would be of particular benefit in this area, maintaining generalisability while 
still providing an opportunity to gain a deeper understanding of patients’ experiences of AS 
and PCa generally [7]. The value of this approach is illustrated in men’s description of 
uncertainty. In qualitative studies, participants described overwhelming uncertainty that 
continued throughout AS [32-34], whereas in quantitative studies, uncertainty reportedly 
decreased over time. This discrepancy warrants further exploration. This review returned no 
qualitative papers relating to anxiety or depression; a qualitative study examining these 
outcomes may have presented different findings, as was the case with uncertainty.  
Limitations of the review 
Due to the absence of universal measures for each psychological dimension studied, and 
indeed consistency in the definitions of each psychological dimension e.g. interchangeable 
use of the terms distress and depression, it was not possible to combine the data of multiple 
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quantitative studies in a meta-analysis. Because of the small number of qualitative studies 
included, a meta-synthesis was also not feasible.  
Although attempts were made to minimise the impact of the use of varying terminology for 
the process of AS, by using multiple terms in the search strategy (Fig. 1), it remains a 
possibility that studies using different terminology for AS/studies failing to provide sufficient 
definitions for the management programme assessed, were not retrieved. 
The papers included in this review were also checked against those studies included in 
previous systematic reviews [5, 6]; neither review uncovered additional papers, aside from 
those discussed as limitations previously, i.e. inclusion of WW papers.  
Recommendations for future research  
Future research should include appropriate comparison groups, timelier baseline measures, 
and steps to minimise selection bias. Ideally, baseline assessment should occur prior to 
treatment decision-making with the aim of assessing patients over time to determine potential 
temporal variability, thereby controlling for individual differences.  The value of longitudinal 
data has been highlighted, evident in the non-linear declines in anxiety. Although overall 
anxiety declined up to 30-months, demonstrating increasing resilience over time, anxiety 
peaked at certain time-points. This fluctuation was particularly pertinent at follow-up 
appointments or while awaiting results [19]. Cross-sectional data would not have detected 
this variability.  
None of the included studies utilised a MM design. The use of this design would facilitate a 
more comprehensive understanding of the impact of AS on men, allowing researchers to 
better understand the holistic needs of patients without compromising generalisability.  
Finally, researchers should cooperate to standardise the psychological measures used in AS 
research therefore facilitating comparison and aiding transferability of international AS 
expertise.  
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Recommendations for practice 
Clinicians reading previous reviews and managing the care of men undergoing AS, could 
easily assume the favourable wellbeing of men receiving AS. Results of the present review 
discuss the various reasons why this may not necessarily be accurate. Evidence should be 
interpreted with consideration for the limitations discussed. Patients with favourable-risk PCa 
deciding on treatment options may require additional reassurance and support when 
considering AS and continuing this monitoring strategy.   
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Table 1. Study characteristics  
Study Design 
Assessment 
period Setting, country; total sample/response rate 
Participants (N; age, years; time on AS at 
assessment) Comparison MMAT 
[12] Cross-sectional NR UH. Australia. 260/33% 86; 65.7; 43 mths on AS None ** 
[13]  Cross-sectional  2007-2012 CC. Italy. 154/67% 103; 67; 10 months post-biopsy None **** 
[14] Cross-sectional NR CC. Britain. 493/67% 329, 100 AS; 67.12; 28.61 months Currently undergoing AT and 
Previously underwent AT 
*** 
[15] Longitudinal  2001-2005 CC. Australia. 211/91.4% (not split by treatment group)  T1: 193 – 61 WW; T2: 172 – 55 WW; 
Demographics not split by treatment group – 
66.15 years; Diagnosis/early treatment; 
12months later 
RP, HT ** 
[16] Cross-sectional  2007-2008 Support group database. USA. NR.  34; 63.1; 14.1 months None * 
[17] Cross-sectional  NR Cancer registry, physician referral/advertisement. USA 
and Ireland. Irish sample 92/10.8%, USA sample NR. 
Ireland 10; 76.5; mean 27.6months 
USA 19; 76; mean 48.5months 
AS men in south of Ireland and USA * 
[18] Longitudinal 1997-2002 Community/University clinic. USA. NR.  105; 75.5; >6 months Those who ceased AS for AT ** 
[19] Longitudinal  2006-2012 CC. USA.180/71% 180; 67.2; <6 months  None *** 
[20] Longitudinal  NR Database. USA. 195/100% 195; 66.5; commencement None  *** 
[21] Longitudinal 2007-2010 Urology dept., USA. 864/77% (Response rate not 
divided by treatment group) 
122; 60.5; >6 months RP **** 
[22] Cross-sectional  2010 CC. Switzerland. 283/44.9% 133 couples; patients 69.3 years; Range 17-136 
months  
None ** 
[23] Longitudinal NR CC. Germany, France, Spain, Italy, Sweden. 672/48.5% 
(not divided by treatment group) 
12 WW/AS; Demographics not split by 
treatment type – 65 years; <2 months of 
diagnosis, 3 months, 12 months  
RP, External beam RT, brachytherapy, 
combined HT and RT, HT, RP 
followed by salvage RT 
*** 
[24]* Cross-sectional 2007-2008 UH. The Netherlands. Sample 150/86%. 129; 64.9; 2.2 months  None **** 
[25]* Longitudinal  2007-2008 UH. The Netherlands. 150/86% 129; 64.3 years; 0-6months  None *** 
[26]* Cross-sectional  NR UH. The Netherlands. (AS sample only) 150/86% 129 AS; 64.9; 6 and 18 months post-diagnosis AT  *** 
[27]* Longitudinal 2007-2008 UH. The Netherlands. Sample: 150/86% 129; 64.6; <6months since 
diagnosis/commencing AS 
None *** 
[28] Cross-sectional  NR Physician referral/advertisement. USA. NR. 19; 76; 4.5 years None * 
[29] Cross-sectional 2012 CC. England.426/73.47%  313; 70.49; >2 months, mean NR. None * 
[30] Cross-sectional 2013 Database. Australia. 67/77% 47; 62; NR None *** 
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[31] Cross-sectional  2007-2011 UC. USA. 452/16% 71; 65.4; 16.52 months None ** 
[32] Qualitative, cross-
sectional 
NR Database. Sweden. 8/87.5%  7; 62-6; 16-35 months None *** 
[33] Qualitative, cross-
sectional 
NR UC. USA. 6/100% 6; 70; >6 months AS None ** 
[34] Qualitative, cross-
sectional 
NR CC. Canada. 45/55.5% 25; 68; <2 years None ** 
*The same cohort of 129 participants were studied in multiple papers  [25-28]  
For further breakdown of the MMAT scores please contact the first author.   
Abbreviations: not reported (NR); cancer clinic (CC); urology clinic (UC); University Hospital (UH); patients/participants (pts); active surveillance (AS); watchful waiting (WW); radical prostatectomy (RP); 
radiotherapy (RT); active treatment (AT); hormone therapy (HT). 
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Table 2. Scales used 
 STUDY 
SCALES 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 
HADS-A:  Hospital and Anxiety Depression Scale-Anxiety 
subscale 
X                       
STAI-T: State-Trait Anxiety Inventory-trait subscale X                       
MAX-PC:  Memorial Anxiety Scale for Prostate Cancer X    X  * ** X  X  X X  X X  X     
Symptom checklist  X                      
Mini-MAC: Mini-mental adjustment to cancer  X                      
HADS:  Hospital and Anxiety Depression Scale   X        X X      X      
BSI-53:  Brief Symptom Inventory    X                    
MUIS:  Mishel’s Uncertainty in Illness Scale     X   X                
CMS: Fife Constructed Meaning Scale     X                   
MHI-5:  Mental health index-5     X                   
SE: Lepore’s self-efficacy for prostate symptom management scale     X                   
MUIS-C: Mishel Uncertainty in Illness Scale− Community form      X           X       
Folkman and Lazarus Appraisal Scale      X           X       
STAI-S: State-Trait Anxiety Inventory-state subscale        X                
EPIC:  Expanded Prostate Cancer Index Composite        X                
SF-12:  Short form Health Survey         X                
EPIC-26:  Expanded Prostate Cancer Index Composite short form         X               
AUA-SI: American Urological Association – Symptom Index         X               
PHQ-9: Patient health questionnaire          X              
GAD-7:  General Anxiety Disorder Scale          X              
DT:  Distress thermometer          X              
WPAI: Work Productivity Assessment Index            X            
DCS:  Decisional Conflict Scale             X X  X        
CES-D:  Centre for Epidemiologic Studies Depression             X X X X        
STAI-6: State-Trait Anxiety Inventory short form             X X X X        
EPQ: Eysenck Personality Questionnaire             X X          
Charlson Comorbidities Index                    X    
MOCS: Measure of Current Status Scale A                    X    
PCPC: The profile of Concerns about PCa                    X    
IES-R: Impact of Event Scale-Revised.                    X    
Qualitative interviews                     X X X 
*3 items only  ** Fear of Recurrence subscale only 
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Table 3. Variables associated with each psychological outcome. 
Psychological outcome 
↑ Anxiety ↑ Depression ↑ Uncertainty 
↓Number of cores at biopsy [12] 
↓Age [13, 24] 
↑Time since diagnosis [13] 
Receipt of curative treatment [17] 
↓QoL [18] 
↑Fear of progression [18] 
↓Time on AS [12, 18, 19, 24] 
↑Role of the physician [12, 23, 
29] 
↓QoL [23]  
MH impairment [12] 
↑Neuroticism [23] 
↑PSA [23] 
↑Uncertainty [27] 
Divorce, lack of partner [12, 28] 
↓PCa knowledge [29] 
↓Coping [30]  
↑PCa concerns [30] 
↓Optimism [30] 
↑Time since diagnosis [13] 
↓QoL [13] 
↑Neuroticism [24] 
 
↓Time since diagnosis [18] 
↓QoL [18] 
↑Fear of progression [18] 
↑Role of the physician↑ [24] 
↑Neuroticism [24] 
↑Anxiety [27] 
↑Perception of danger [27] 
Perceptions of being ‘alone’ [31] 
Compromised masculinity [31, 33] 
Conflicting relationship with physician 
[31, 32] 
Fear/worry, ‘risking one’s life’ [31, 
32] 
Fear of treatment failure/disease 
recurrence/spread [32, 33] 
↑Side effects [32, 33] 
Temporal variability of uncertainty 
[33] 
↓age and increased biopsy pain – 
patients compared biopsy with rape 
[33] 
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Figure 1. PRISMA Flow Diagram (study selection and search terms 
 
 
 
Additional records identified through other sources 
(reference lists and Google Scholar  
(n = 10) 
Titles screened  
(n = 9412) Records excluded  
(n = 8671) 
Full-text articles assessed 
for eligibility  
(n = 205) 
Full-text articles excluded  
(n = 182) 
Reasons:  
 Patients not on AS 
 Patients not yet made treatment 
decision 
 WW used as a palliative care 
approach 
 Focus on medical side of AS 
 Psychological variables not 
assessed  
 Results not split by treatment type 
 Studies only assessing QoL (n= 18) 
 Studies included in final 
synthesis  
(n = 23) 
Abstracts screened 
(n = 741) 
Records excluded  
(n = 536) 
 
Records after duplicates removed  
(n = 9412) 
Records identified through 
database searching (CINAHL, 
InterNurse, Embase, Medline, 
PsycINFO, PsycARTICLES, and Web of 
Science). 
(n = 11270) 
Search terms 
Prostatic Neoplasms [MeSH] OR Prostat* AND (Cancer OR Tumour OR Tumor OR Neoplasm) AND (Active 
Surveillance OR Disease Surveillance OR Expectant Treatment OR Expectant Management OR Watchful 
Waiting OR Observation) AND (Stress, Psychological [MeSH] OR Anxiety [MeSH] OR Quality Of Life [MeSH] 
OR Uncertainty [MeSH] OR Psychology [MeSH] OR Adaptation, Psychological [MeSH] OR Psych* OR 
Coping).  
 
 
